Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Combination immunotherapy and targeted therapy regimens show favorable survival outcomes versus monotherapies in unresectable hepatocellular carcinoma
New Data Reveals Which Liver Cancer Treatments Work Best Over Time
This systematic review and pooled analysis of parametric survival curves from 15 randomized controlled trials evaluated first-line treatment…
This research shows that combining two different cancer drugs helps patients live longer than using just one, but the benefit isn't constant…
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Research across Hepatocellular Carcinoma
Related studies from across the Hepatocellular Carcinoma family.
Evidence-based guidelines support team-based perioperative glycemic management for patients with hepatocellular carcinoma
New guidance for blood sugar control before liver cancer surgery
This evidence summary synthesizes 14 documents, including guidelines and randomized controlled trials, to provide guidance on perioperative …
A new evidence summary offers 28 best practice items for managing blood sugar in liver cancer patients before, during, and after surgery.
Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development
Elevated M2BPGi Levels Linked to Higher Risk of Liver Cancer
This systematic review and meta-analysis of 12,161 participants found that elevated serum M2BPGi is significantly associated with an increas…
A large review of over 12,000 patients found that high levels of a specific protein may signal an increased risk for liver cancer.
Image-guided RFA and MWA show comparable efficacy and safety for small to medium hepatocellular carcinoma
Radiofrequency and microwave ablation show similar results for liver cancer
This meta-analysis of 19 studies compared image-guided radiofrequency ablation (RFA) and microwave ablation (MWA) for small to medium hepato…
Two common types of heat-based treatments for small to medium liver cancer show nearly identical success rates and safety profiles.
Direct-acting antivirals achieve 89% sustained virologic response in patients with hepatocellular carcinoma and HCV
Direct-acting antivirals show promise for patients with liver cancer
This meta-analysis of 8,839 patients with hepatocellular carcinoma (HCC) and Hepatitis C virus infection found that direct-acting antivirals…
New data suggests that direct-acting antiviral drugs may improve survival and reduce cancer recurrence for people with Hepatitis C and liver…
Radiomics-based artificial intelligence models predict VETC presence in patients with hepatocellular carcinoma
AI helps predict aggressive liver cancer growth patterns
Researchers evaluated the diagnostic accuracy of radiomics-based AI models using various imaging modalities to identify vessel-encapsulated …
New AI tools can identify specific high-risk markers in liver cancer scans, helping doctors better predict which tumors are likely to return…
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression
Immune system crosstalk drives fatty liver disease progression
This systematic review examines the role of immune system interactions in metabolic dysfunction-associated steatotic liver disease (MASLD) a…
A new review reveals that immune cells talking to each other may be what pushes fatty liver disease toward severe liver damage.
Mendelian Randomization Evaluates IL-6 Inhibition Effects on Hepatocellular and Colorectal Cancer Risk
Genetic data shows tocilizumab does not cause specific cancers
Genetic modeling suggests that IL-6 inhibition does not causally increase the risk of hepatocellular or colorectal cancers in diverse popula…
New genetic modeling suggests the drug tocilizumab does not increase the risk of liver or colorectal cancers for patients.
Combination of Local Treatment and Systemic Therapy Improves Outcomes in Patients with Hepatocellular Carcinoma
Combining local and systemic treatments improves survival in liver cancer
This meta-analysis evaluated the addition of local treatments like TACE or HAIC to systemic therapy involving immune checkpoint inhibitors a…
Adding local treatments like TACE or HAIC to immunotherapy can improve response rates and extend survival for patients with hepatocellular c…
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
New analysis links diabetes drugs to liver outcomes in millions of patients
This network meta-analysis evaluated major adverse liver outcomes among 7124845 adults with type 2 diabetes using glucose-lowering drug clas…
A massive analysis of millions of patients found some diabetes medications linked to lower risks of serious liver events compared to others.
Combining Pentraxin-3 and AFP increases sensitivity to 0.92 for hepatocellular carcinoma diagnosis in chronic liver disease
New blood test helps doctors find liver cancer earlier with better accuracy than old methods alone
This systematic review and meta-analysis evaluated diagnostic markers in adults with chronic liver disease suspected of hepatocellular carci…
A review of 1,179 patients shows a new marker called PTX3 works well for finding liver cancer. Using both PTX3 and AFP together finds more c…
Questions about Unresectable Hepatocellular Carcinoma
Does adding camrelizumab improve outcomes for unresectable hepatocellular carcinoma patients?
Adding camrelizumab to standard treatments like TACE and targeted drugs significantly improves tumor response, disease control, and survival times for patients with unresectable hepatocellular carcinoma.
Full answer →Can triple therapy help patients with unresectable hepatocellular carcinoma live longer?
Yes, triple therapy (TACE plus targeted drugs and immunotherapy) can help patients with unresectable hepatocellular carcinoma live longer, with studies showing improved overall survival and progression-free survival compared to TACE alone or double therapy.
Full answer →Does having HBV make surgery more likely for unresectable hepatocellular carcinoma?
Having hepatitis B virus (HBV) infection is linked to a higher chance of surgical conversion for patients with unresectable hepatocellular carcinoma treated with triple therapy.
Full answer →